The only small-molecule therapeutic currently approved for SMA is risdiplam, an orally administered compound that promotes inclusion of exon 7 in SMN2 transcripts, thereby enhancing production of full-length SMN protein [9,10,11]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.